Last updated on December 2018

A Post Authorisation Registry of IMNOVID (Pomalidomide) for Patients With Relapsed and Refractory Multiple Myeloma.

Brief description of study

This registry is a prospective, multi-center, observational study and will collect safety data on multiple myeloma adult patients who have received at least two prior therapies and take IMNOVID (pomalidomide) as part of standard care.

The registry will remain open until 500 patients will have received at least 3 cycles of pomalidomide. All patients registered will be followed up prospectively for up to 3 years following the end of pomalidomide treatment. During this time the incidence of second primary malignancies (SPM), overall survival and any occurrence of a pregnancy will be assessed.

Clinical Study Identifier: NCT02164955

Contact Investigators or Research Sites near you

Start Over

Associate Director, Clinical Trial Disclosure

IC0 Duran y Reynalds
Barcelona, Spain
  Connect »

Associate Director, Clinical Trial Disclosure

Hospital Universitari Vall d'Hebron
Barcelona, Spain
  Connect »

Associate Director, Clinical Trial Disclosure

Hospital Universitari Germans Trias i Pujol
Badalona, Spain
  Connect »

Recruitment Status: Open

Brief Description Eligibility Contact Research Team

Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.